Literature DB >> 19655117

The pharmacology of voltage-gated sodium channels in sensory neurones.

Reginald J Docherty1, Clare E Farmer.   

Abstract

Voltage-gated sodium channels (VGSCs) are vital for the normal functioning of most excitable cells. At least nine distinct functional subtypes of VGSCs are recognized, corresponding to nine genes for their pore-forming alpha-subunits. These have different developmental expression patterns, different tissue distributions in the adult and are differentially regulated at the cellular level by receptor-coupled cell signalling systems. Unsurprisingly, VGSC blockers are found to be useful as drugs in diverse clinical applications where excessive excitability of tissue leads to pathological dysfunction, e.g. epilepsy or cardiac tachyarrhythmias. The effects of most clinically useful VGSC blockers are use-dependent, i.e. their efficacy depends on channel activity. In addition, many natural toxins have been discovered that interact with VGSCs in complex ways and they have been used as experimental probes to study the structure and function of the channels and to better understand how drugs interact with the channels. Here we have attempted to summarize the properties of VGSCs in sensory neurones, discuss how they are regulated by cell signalling systems and we have considered briefly current concepts of their physiological function. We discuss in detail how drugs and toxins interact with archetypal VGSCs and where possible consider how they act on VGSCs in peripheral sensory neurones. Increasingly, drugs that block VGSCs are being used as systemic analgesic agents in chronic pain syndromes, but the full potential for VGSC blockers in this indication is yet to be realized and other applications in sensory dysfunction are also possible. Drugs targeting VGSC subtypes in sensory neurones are likely to provide novel systemic analgesics that are tissue-specific and perhaps even disease-specific, providing much-needed novel therapeutic approaches for the relief of chronic pain.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19655117     DOI: 10.1007/978-3-540-79090-7_15

Source DB:  PubMed          Journal:  Handb Exp Pharmacol        ISSN: 0171-2004


  6 in total

1.  Effect of Homocysteine on Voltage-Gated Sodium Channel Currents in Primary Cultured Rat Caudate Nucleus Neurons and Its Modulation by 2-Arachidonylglycerol.

Authors:  Ziliang Zou; Yongli Lu; Manman Dong; Hongwei Yang
Journal:  J Mol Neurosci       Date:  2015-07-16       Impact factor: 3.444

Review 2.  Current and Future Issues in the Development of Spinal Agents for the Management of Pain.

Authors:  Tony L Yaksh; Casey J Fisher; Tyler M Hockman; Ashley J Wiese
Journal:  Curr Neuropharmacol       Date:  2017       Impact factor: 7.363

Review 3.  Basic/Translational Development of Forthcoming Opioid- and Nonopioid-Targeted Pain Therapeutics.

Authors:  Nebojsa Nick Knezevic; Ajay Yekkirala; Tony L Yaksh
Journal:  Anesth Analg       Date:  2017-11       Impact factor: 5.108

4.  Endocannabinoid 2-arachidonylglycerol protects primary cultured neurons against LPS-induced impairments in rat caudate nucleus.

Authors:  Yongli Lu; Fang Peng; Manman Dong; Hongwei Yang
Journal:  J Mol Neurosci       Date:  2014-02-09       Impact factor: 3.444

5.  Modulation Effects of Cordycepin on Voltage-Gated Sodium Channels in Rat Hippocampal CA1 Pyramidal Neurons in the Presence/Absence of Oxygen.

Authors:  Zhi-Bin Liu; Chao Liu; Bin Zeng; Li-Ping Huang; Li-Hua Yao
Journal:  Neural Plast       Date:  2017-10-31       Impact factor: 3.599

6.  Co-Application of Eugenol and QX-314 Elicits the Prolonged Blockade of Voltage-Gated Sodium Channels in Nociceptive Trigeminal Ganglion Neurons.

Authors:  Sung-Min Hwang; Kihwan Lee; Sang-Taek Im; Eun Jin Go; Yong Ho Kim; Chul-Kyu Park
Journal:  Biomolecules       Date:  2020-11-05
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.